Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine plus Nab-Paclitaxel Chemoradiotherapy for LAPC
NCT02272738Phase 1Completed
- Sponsor
- Osaka International Cancer Institute
- Start
- Aug 2013
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by Osaka International Cancer Institute. Primary endpoint: Number of patients with Adverse Events at 1 year. Started Aug 2013; status: completed.
02
Drugs
paclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02272738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02272738.